NIH abandons convalescent plasma trial in mild COVID

Another trial of convalescent plasma in people with COVID-19 has missed the mark, this time in mild to moderate disease, further dashing hopes that the therapy could have an impact on the i

Data sets up ulcerative colitis expansion for BMS’ MS drug Z...

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – and new data in ulcerative colitis suggests they could climb

IL-6 hypothesis looking shaky as Kevzara fails COVID-19 tria...

Hopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results from the first large-scale trial of Sanofi

Kadmon preps filing for GVHD drug belumosudil after phase 3 ...

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.

Innovating in inflammation and immunology

For World Inflammatory Bowel Disease day we spoke to Pfizer’s Matt Shaulis, president of international developed markets for inflammation and immunology, to hear how the company hopes to ha

Blockbusters in waiting: drug launches to watch in 2020